ag 1295 has been researched along with pd 153035 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Gangjee, A; Ihnat, MA; Namjoshi, OA; Thorpe, JE; Warnke, LA; Yu, J | 1 |
| Cody, V; Gangjee, A; Green, DW; Ihnat, M; Li, W; Lin, L; Pace, J; Queener, SF; Warnke, LA; Zeng, Y | 1 |
| Buchanan, A; Gangjee, A; Ihnat, MA; Namjoshi, OA | 1 |
| Gangjee, A; Ihnat, MA; Raghavan, S; Thorpe, JE; Yang, J; Zaware, N | 1 |
| Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Namjoshi, OA; Thorpe, JE; Yu, J | 1 |
6 other study(ies) available for ag 1295 and pd 153035
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Sensitivity and Specificity; Stereoisomerism; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.
Topics: Animals; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Molecular Structure; Pyrimidines; Rats; Receptor Protein-Tyrosine Kinases; Tetrahydrofolate Dehydrogenase | 2009 |
The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines.
Topics: Angiogenesis Inhibitors; Catalytic Domain; Cell Line, Tumor; Computer Simulation; ErbB Receptors; Humans; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Design; Humans; Indoles; Mice; Mice, Nude; Molecular Dynamics Simulation; Neoplasms; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastati
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Design; Humans; Melanoma, Experimental; Mice; Mice, Nude; Microwaves; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |